



Lynn L. Janulis, Ph.D.

Partner

Tel 312.474.6637 ljanulis@marshallip.com

Clients seeking advice in establishing and maintaining patent portfolios worldwide in all areas of biotechnology and pharmaceuticals can benefit from the education and experience of Lynn L. Janulis, Ph.D. Her advanced graduate and post-doctoral scientific training in molecular and developmental biology, reproductive endocrinology and cancer, along with her legal experience, allow her to counsel clients in strategic management of their scientific intellectual property. She assists clients in obtaining worldwide patent rights with her experience in patent prosecution, opinions, due diligence analyses, and interference proceedings. Lynn strives to understand and meet the needs of her clients, from non-profit institutions to international companies.

For her exceptional efforts in leading the advancement of diversity, equity, and inclusion at the firm, Lynn has been recognized among 2023 *Crain's Chicago Business* Notable Leaders in DEI. From 2014–2018, she was selected for inclusion in the *Illinois Rising Stars*[®] list, featuring outstanding young attorneys in the state. She was also designated as an "Emerging Lawyer" by *Emerging Lawyers Magazine*. Since 2018, Lynn has been recognized as a "Leading Lawyer" by Leading Lawyers, a division of *Law Bulletin Publishing Company*. In 2022, Lynn was recognized as a Women Worth Watching by *Profiles in Diversity Journal*. Lynn has recently been recognized as one of World Intellectual Property Review's 2024 Top 100 leaders driving positive change in the IP community

Practices

- Patent Prosecution
- Post-Grant Patent Proceedings

Industries

- Biotechnology & Life Sciences
- Non-Profit Technology Transfer
- Pharmaceuticals

Representative Experience

 Assisted in obtaining patent protection for a client's compound whose sales are expected to exceed a billion dollars annually. Helped develop a patent prosecution strategy that ultimately gave rise to international patent protection, and helped position the client to acquire even broader protection by in-licensing its competitors' related technologies.



- Counseled medical products client through patent application processes and freedom-to-operate issues in their development of a vaccine product to protect against human and animal disease.
- Successfully drafted and secured patents relating to several recombinant growth factor polypeptides, antibodies, and their medical uses for client's leading biotechnology company.
- Obtained patent protection for plant bioscience products and plant patents.

Lynn has handled matters in a wide variety of biotechnology areas, such as:

- Antibodies
- Diagnostics and pharmaceuticals
- Genomics and proteomics
- Growth factors, developmental biology, and cancer biology
- Immunogenic and vaccine compositions
- Pharmacology and pharmaceutics
- Plant biosciences
- Plant patents
- Stem cells
- Therapeutics and physiological treatment of disease
- Transgenic animals

Background and Credentials

Along with her patent portfolio work for diverse biotechnology and pharmaceutical clients, Lynn has extensive experience in preparing opinions, conducting due diligence analyses, patent searches and legal research, preparing legal memoranda, and advising clients regarding their IP management. She has assisted a wide range of clients, including Fortune 500 companies, start-up companies, and university technology transfer offices.

Lynn concentrates her practice on securing patent rights in the life science technologies. She has extensive knowledge in the fields of biotechnology, including molecular biology, virology, microbiology, immunology, biochemistry, and pharmaceuticals. Among her specific areas of interest are reproductive biology, developmental and animal biology, cancer, vaccines, stem cell technologies, antibodies, pharmaceutical compositions, recombinant organisms and expression systems, recombinant proteins and methods of production and use, transgenic animals, plant biosciences, plant patents, assays and diagnostic methods, and methods of treatment of various diseases and disorders.

Lynn received her J.D. from The John Marshall Law School. She earned her Ph.D. in molecular and reproductive endocrinology from the University of Illinois at Urbana-Champaign, and was a postdoctoral fellow in the Department of Urology at Northwestern University Medical School prior to joining Marshall Gerstein.

During her graduate and postdoctoral training, Lynn received fellowships from the National Institutes of Health and the American Foundation for Urologic Disease. Her postdoctoral research involved the study of prostate and other urologic cancers as well as the developmental biology of the prostate. Her graduate research involved the discovery of P450 aromatase, the estrogen synthesizing enzyme, in germ cells in the male reproductive system.

Education

• The John Marshall Law School (J.D.)



- Intellectual Property Law (Certificate)
- University of Illinois, Urbana-Champaign (Ph.D.)
 Reproductive Endocrinology/Physiology
 - University of Illinois, Urbana-Champaign (M.S.)
 - Reproductive Endocrinology/Physiology
- University of Illinois, Urbana-Champaign (B.S.)
 - Animal Biology

Bar Admissions

- Illinois
- U.S. Patent and Trademark Office

Publications and Presentations

Lynn has published her research in scientific journals, and she has written several book chapters on the subjects relating to her research. She has also presented CLE seminars on developments in case law as it relates to patent prosecution.

- Zhou W, Janulis L, Park II, Lee C. A novel anti-proliferative property of clusterin in prostate cancer cells. Life Sci 2002; 72:11-21.
- Lee C, Janulis L, Ilio K, Shah A, Park I, Kim S, Cryns V, Pins M, Bergan R. *In vitro* models of apoptosis: clusterin as an antiapoptotic mediator. Prostate Suppl 2000; 9:21-24. Review.
- Janulis L, Nemeth J, Yang T, Lang S, Lee C. Prostatic luminal cell differentiation and PBP gene expression are differentially affected by neonatal castration. Prostate 2000; 43:195-204.
- Janulis L, Grayhack J, Lee C. Endocrinology of the prostate, Chapter 5, p. 59-74. In: Prostatic Diseases. Lepor H (ed) 2000 WB Saunders, Philadelphia.
- Lee C, Janulis L, Ilio K, Shah A, Park I, Kim S, Cryns V, Pins M, Bergan R. *In vitro* models of prostate apoptosis: clusterin as an antiapoptotic mediator. Prostate Supp 2000; 9:21-24.

Access Lynn's additional Publications and Presentations.

Community and Professional Involvement

- AUTM
- Cabrini Green Legal Aid, Chicago: pro bono work
- Intellectual Property Law Association of Chicago (IPLAC)
- Past Membership Committee Chair, Past Communications Committee Vice Chair, Women In Bio-Chicago Chapter

Insights



June 16, 2020

An Employer Who Fires an Individual Merely for Being Gay or Transgender Defies the Law Marshall Gerstein Alert

2002

"A novel anti-proliferative property of clusterin in prostate cancer cells"

Life Sci; 72:11-21

2000

"Down-regulation of TGF-β1 production restores immunogenicity in prostate cancer cells" Brit J Cancer;83:519-525

2000

"In vitro models of prostate apoptosis: clusterin as an antiapoptotic mediator" Prostate Supp; 9:21-24

2000

"In: Prostatic Diseases"

Lepor H (ed). WB Saunders, Philadelphia

2000

"Prostatic luminal cell differentiation and PBP gene expression are differentially affected by neonatal castration"

Prostate

2000

"In vitro models of apoptosis: clusterin as an antiapoptotic mediator" Prostate Suppl: 9:21-24. Review.

1999

"Transforming growth factor-□ type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells"

Urology; 54: 164-107

1999

"Transforming growth factor-β in benign and malignant prostate" Prostate; 39:285-290

1999

"Prostate gland"

Encyclopedia of Reproduction. Knobil E, Neill JD (eds) 1999 Academic Press.

1998

"Rat testicular germ cells and epididymal sperm contain active P450 aromatase" J Androl; 19:65-71

1998

"Characterization of domains in mice of calnexin-t, a putative molecular chaperone required in sperm fertility, with use of glutathione-s-transferase-fusion proteins" Biol Reprod; 59: 1214-1223



1998

"Absence of expression of transforming growth factor-□ type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca." J Urol; 160: 1883-1888

1996

"Mouse epididymal sperm contain active P450 aromatase which decreases as sperm traverse the epididymis" J Androl; 17: 111-116 (journal cover)

1996

"P450 aromatase messenger ribonucleic acid expression in male rat germ cells: detection by reverse transcription-polymerase chain reaction amplification"

J Androl; 17: 651-658

1995

Rooster testicular germ cells and epididymal sperm contain P450 aromatase. Biol Reprod; 53: 1259-1264

1993

"Germ cells of the mouse testis express P450 aromatase" Endocrinology; 132: 1396-1401 (journal cover)

1991

Technical Report - Obtaining blood samples from rabbits

Handbook of Methods for Study of Reproductive Physiology in Domestic Animals

1986

"A fluorescent polarization immunoassay for the determination of urinary 5-hydroxy-3-indoleacetic acid"

Clinical Chemistry; 32 (6): 1122-1123